Microbial Metabolism and Disease

Microbial Metabolism and Disease

1st Edition - March 13, 2021

Write a review

  • Author: Elena Paley
  • Paperback ISBN: 9780323884457
  • eBook ISBN: 9780323884464

Purchase options

Purchase options
DRM-free (Mobi, PDF, EPub)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order


Microbiome Metabolic Pathways and Disease provides insight into the interaction of microbial metabolic pathways in the human body and the impact these can have on a variety of diseases. By analyzing these pathways the book seeks to investigate how these metabolic processes can be targeted and manipulated in order to treat various disorders and diseases. Topics covered in the book include microbial shikimate pathways, protein biosynthesis, tryptophan metabolites, microbiome metabolic engineering, fecal microbiota transplantation, and virulence factors. Additionally, a variety of conditions are covered, such as disorders associated with metabolic syndromes, serotonin syndromes, Alzheimer’s disease, and Covid-19, providing a detailed overview of how metabolic pathways of microbiome can impact health and disease in the human body.

Key Features

  • Explores microbial metabolic pathways in the human body and implications for disease
  • Investigates specific steps involved in metabolic reactions in the human microbiome, including shikimate pathways and tryptophan pathways
  • Considers a variety of diseases and disorders, such as Alzheimer’s disease, metabolic syndromes, Crohn’s disease and Covid-19
  • Includes analysis of various amino acids and enzymes in microbial and human cells and how these can impact health


Molecular biologists, biochemists, microbiologists, pharmacologists. Graduate, PhD and postdoctoral researchers working in the areas of molecular biology, biochemistry, microbiology, biomedicine and related fields

Table of Contents

  • 1. Naturally occurring affectors of initial step of protein biosynthesis
    1.1 Abstract
    1.2 Introduction
    1.3 Experimental evidences supporting the concept
    1.3.1 Tryptamine-induced neurodegeneration in cell and animal models
    1.3.2 Alzheimer’s disease (AD) is a systemic widespread disease
    1.3.3 Seizures and myoclonus in Alzheimer's disease and in tryptamine-treated animals
    1.3.4 Serotonin (5-HT) or tryptamine syndrome
    1.3.5 Metabolic syndrome
    1.3.6 Tryptamine, biogenic amines (BA) and polyamines affect tRNA aminoacylation and protein biosynthesis
    1.3.7 Protein biosynthesis in Alzheimer’s disease and in cancer
    1.3.8 Mutations of genes encoding cytoplasmic (WARS) and mitochondrial (WARS2) TrpRS leading to TrpRS deficiency, Parkinsonism and cognitive impairment
    1.3.9 The accumulation of defective proteins induces antigenicity
    1.3.10 Conclusion

    2. Physicochemical, biochemical and cell biology properties and byproducts of tryptamine and other “trace” amines

    3. Tryptophan metabolites and biogenic amines in physical exercises

    4. Tryptamine in inflammation and regulation of gene transcription

    5. Genes encoding mammalian, plant and microbial aromatic amino acid decarboxylase
    5.1 Mammalian aromatic acid decarboxylase
    5.2 Bacterial aromatic L-amino acid decarboxylases
    5.3 Fungal pyridoxal-dependent aromatic-L-amino-acid decarboxylase
    5.4 Plant tryptophanyl-tRNA synthetase
    5.5 Conclusion

    6. Decarboxylases producing tryptamine and other biogenic amines in human microbiome

    7. Microbial shikimate pathway in diseases
    7.1 Apicomplexan parasites
    7.2 Effect of tryptamine and other tryptophan related compounds on shikimate pathway enzymes
    7.3 Pyridoxal phosphate (PLP)-dependent enzymes
    7.4 Metabolic engineering
    7.5 Inhibitors of shikimate pathway enzymes
    7.6 Conclusion

    8. Biogenic amines in fasting, feeding and stress conditions
    8.1 Fasting and feeding
    8.2 Anorectic effect
    8.3 Stress factors
    8.4 Stress and mucus
    8.5 Irritable bowel syndrome: poor sleep
    8.6 Conclusions

    9. Metabolites of shikimate and tryptophan pathways in Corona virus disease (COVID-19)
    9.1 Comparison of statistics for age-related diseases COVID-19 and Alzheimer’s disease
    9.2 Proteomic and metabolomic profiling of sera from COVID-19 patients and further discussion
    9.3 Postmortem studies of COVID-19 patients in different countries
    9.4 Conclusions

    10. Virulence factors
    10.1 Bacteria and virus interactions in influenza
    10.2 Decarboxylase and viral infection
    10.3 Emerging data suggest that microbial tryptophan catabolites resulting from shikimate pathway, diet and human proteolysis are influencing host health
    10.4 Toxicological effects of biogenic amines and postmortem examinations of Serotonin Syndrome cases
    10.4.1 Toxicological effects of biogenic amines
    10.4.2 Postmortem study of Serotonin Syndrome cases
    10.5 Biogenic amines and amino acid decarboxylases as virulence factors
    10.5.1 Tyramine, histamine, putrescine as virulence factors
    10.5.2 Tryptamine as virulence and anaphylaxis factor
    10.5.3 Spermine, spermidine, tyramine and tryptamine in viral infection
    11. Relation of human gut Alzheimer’s disease associated sequence (ADAS) with shikimate pathway metabolites
    11.1 Alterations in human gut microbiome shikimate pathway and metabolites of aromatic amino acids linked to Alzheimer’s disease and associated metabolic disorders
    11.2 Ubiquinone, a substrate of Na(+)-transporting NADH: Ubiquinone reductase related to ADAS
    11.3 Shikimate pathway metabolites 4-hydroxybenzoate, 3–hydroxybenzoate, benzoate and quinate in human fecal samples
    11.4 Aromatic amino acids (AAA) and biogenic amines in human gut

    12. Benefits of using fecal microbiota transplantation as treatment have been controversial

    13. Shikimate pathway enzymes in human microbiome
    13.1 Shikimate pathway and its inhibitor pesticide glyphosate in general human population and in diseases
    13.2 Human microbial metabolic capacity for production of shikimate pathway metabolites
    13.3 Conclusions

    14. Tryptophan operon in human microbiome and inhibitors of tryptophan operon enzymes

    15. Antibodies to tryptamines

    16. Cell death in Alzheimer's disease brain and tryptamine-treated cells

Product details

  • No. of pages: 306
  • Language: English
  • Copyright: © Academic Press 2021
  • Published: March 13, 2021
  • Imprint: Academic Press
  • Paperback ISBN: 9780323884457
  • eBook ISBN: 9780323884464

About the Author

Elena Paley

Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley’s research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending.

Affiliations and Expertise

Founder, President and CEO Expert Biomed Inc.; Co-founder and Director Stop Alzheimer’s Corp.; Adjunct Professor, Nova Southeastern University, FL, USA; The Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

Ratings and Reviews

Write a review

Latest reviews

(Total rating for all reviews)

  • Subbarayan P. Thu Oct 28 2021

    Microbial Metabolism and Disease

    After several decades of neglect Microbes are making a come. This volume is timely. The collection of articles written by experts covers the whole gamut of human health and disease.